scholarly article | Q13442814 |
P819 | ADS bibcode | 2012PLoSO...750005R |
P356 | DOI | 10.1371/JOURNAL.PONE.0050005 |
P932 | PMC publication ID | 3503708 |
P698 | PubMed publication ID | 23185517 |
P5875 | ResearchGate publication ID | 233775692 |
P50 | author | S. Vincent Rajkumar | Q61123608 |
Shaji K Kumar | Q85960198 | ||
P2093 | author name string | Vijay Ramakrishnan | |
Utkarsh Painuly | |||
Jessica Haug | |||
Teresa Kimlinger | |||
Linda Wellik | |||
Timothy Halling | |||
P2860 | cites work | Two distinct human myeloma cell lines originating from one patient with myeloma. | Q52833946 |
Cyclic adenosine-3',5'-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. | Q54116960 | ||
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. | Q54422243 | ||
Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma. | Q54702844 | ||
Treatment of multiple myeloma | Q83975326 | ||
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor | Q22009126 | ||
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase | Q24300915 | ||
Mechanism of activation of protein kinase B by insulin and IGF-1 | Q24309528 | ||
Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation | Q24312168 | ||
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 | ||
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling | Q24536092 | ||
mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 | ||
Phosphorylation and regulation of Raf by Akt (protein kinase B) | Q28138863 | ||
Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency | Q28249019 | ||
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt | Q28255373 | ||
The LKB1 tumor suppressor negatively regulates mTOR signaling | Q28272728 | ||
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins | Q28507365 | ||
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress | Q29614493 | ||
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
Phosphoinositide kinases | Q29618047 | ||
TOR signaling | Q30312086 | ||
Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. | Q30452681 | ||
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma | Q33383550 | ||
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study | Q33942495 | ||
Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria | Q33959022 | ||
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells | Q34134557 | ||
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy | Q34306865 | ||
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. | Q34374071 | ||
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 | ||
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. | Q35256272 | ||
Defining the role of TORC1/2 in multiple myeloma | Q35631315 | ||
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone | Q36663554 | ||
Perifosine: update on a novel Akt inhibitor. | Q37393008 | ||
Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma | Q39465626 | ||
Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival | Q39621100 | ||
ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). | Q39632887 | ||
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. | Q39718152 | ||
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs | Q39771144 | ||
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. | Q39827794 | ||
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. | Q39830937 | ||
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells | Q40087316 | ||
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells | Q40328451 | ||
Analysis of PTEN deletions and mutations in multiple myeloma | Q40383211 | ||
Downstream effectors of oncogenic ras in multiple myeloma cells | Q40679257 | ||
Development and characterization of a melphalan-resistant human multiple myeloma cell line | Q41697179 | ||
mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes | Q42809294 | ||
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma | Q43761443 | ||
Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. | Q43901688 | ||
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications | Q44098361 | ||
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial | Q44442859 | ||
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. | Q46615053 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | e50005 | |
P577 | publication date | 2012-11-21 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway | |
P478 | volume | 7 |
Q38218256 | AKT as a therapeutic target in multiple myeloma |
Q35236076 | Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. |
Q90394240 | Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma |
Q57818334 | Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma |
Q38718211 | Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6. |
Q88287160 | Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation |
Q89964186 | Combination of Rapamycin and MK-2206 Induced Cell Death via Autophagy and Necroptosis in MYCN-Amplified Neuroblastoma Cell Lines |
Q35667885 | Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines |
Q38112176 | Emerging pathways as individualized therapeutic target of multiple myeloma. |
Q36737884 | Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy |
Q37583378 | Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization |
Q33875590 | Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma |
Q37697253 | Kinase inhibitors as potential agents in the treatment of multiple myeloma |
Q35594600 | Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines |
Q35615252 | MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma |
Q38950582 | Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. |
Q38690290 | Novel investigational drugs active as single agents in multiple myeloma. |
Q28081590 | Novel therapeutic strategies for multiple myeloma |
Q53055574 | PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform. |
Q48263465 | PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. |
Q27700745 | Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma |
Q34158470 | Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways |
Q34075096 | Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition |
Q38753307 | Signaling Pathways and Emerging Therapies in Multiple Myeloma |
Q37636618 | Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma |
Q47618731 | The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs |
Q47094892 | Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer |
Q52910208 | [Research on multiple myeloma cell apoptosis by inhibition of mTORC2 and chaperon pathways]. |
Search more.